Commercial Interests at ASCO 2017 - A 1stOncology Insights Report

  • ID: 4302734
  • Report
  • 583 pages
  • Bioseeker
1 of 3

The Commercial Interests at ASCO 2017 report is a must have companion tool for reviewing the direction of commercial drug development emerging from the American Society of Clinical Oncology (ASCO) Annual Meeting 2017. Break through the mountain of close 5,000 abstracts presented at ASCO 2017 with a focused entry to reveal the identity and position of more than 470 commercial drugs at the core of the oncology landscape.

These identified drugs range from early development to marketed and in this report are analyzed across 14 “hot” areas in oncology, including sections such as exciting Startups, Immune checkpoint drugs, Epigenetic therapies, DNA Damage response drugs and many more. Each “hot” area analyzed reveals the core R&D focus of commercial actors, the targeting landscape (with many cases of unique targets not currently under development by any other company), drugs with biomarkers, drugs in combination therapy development and much more.

To further illuminate the reader, this report also includes more than 1,000 references detailing the latest positive and negative pipeline development from throughout 2016 to present for circa two hundred top cancer drugs. This provides comprehensive insight to current developments such as successful clinical trials, trials with missed primary endpoints, new or terminated partnerships, M&A and much more.

The ASCO Annual Meeting is one of the few truly key events on a global scale that tell us the direction of commercial drug development in oncology. This report is a must read for anyone with an interest in oncology who wants to save time and effort and more successfully analyze the direction emerging from this meeting.

Note: Product cover images may vary from those shown
2 of 3

1 Executive Summary

2 About 1stOncology Insights
2.1 Scope and Methodology

3 Table of Contents
3.1 List of Figures
3.2 List of Tables

4 Major Recent Developments on Cancer Drugs at ASCO from 2016 to Present
4.1 Positive Highlights on Cancer Drugs by Highest Stage
4.1.1 Marketed
4.1.2 Pre-registration
4.1.3 Phase III
4.1.4 Phase II
4.1.5 Phase I
4.1.6 Preclinical
4.2 Negative Highlights on Cancer Drugs by Highest Stage
4.2.1 Marketed
4.2.2 Pre-registration
4.2.3 Phase III
4.2.4 Phase II

5 Overview of Cancer Drugs at ASCO 2017
5.1 Pipeline Breakdown and Status
5.2 From Small Molecules to Biologics
5.3 Analysis of the Drug Target Landscape
5.4 Pursued Tumor Types
5.5 Biomarkers and Combination Therapies Review
5.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
5.7 Drug Innovators

6 ASCO 2017 by Startups
6.1 Pipeline Breakdown and Status
6.2 Compound Review
6.3 Target Analysis
6.4 Pursued Tumor Types
6.5 Biomarkers and Combination Therapies Review
6.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
6.7 Drug Innovators

7 ASCO 2017 by Fierce 15 Companies
7.1 Pipeline Breakdown and Status
7.2 Compound Review
7.3 Target Analysis
7.4 Pursued Tumor Types
7.5 Biomarkers and Combination Therapies Review
7.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
7.7 Drug Innovators

8 ASCO 2017 by Orphan Drugs
8.1 Pipeline Breakdown and Status
8.2 Compound Review
8.3 Target Analysis
8.4 Pursued Tumor Types
8.5 Biomarkers and Combination Therapies Review
8.6 Breakthrough Drugs and Sales Data Figures
8.7 Drug Innovators

9 ASCO 2017 by Breakthrough Therapies
9.1 Pipeline Breakdown and Status
9.2 Compound Review
9.3 Target Analysis
9.4 Pursued Tumor Types
9.5 Biomarkers and Combination Therapies Review
9.6 Orphan Drugs and Sales Data Figures
9.7 Drug Innovators

10 ASCO 2017 by Cancer Vaccines
10.1 Pipeline Breakdown and Status
10.2 Compound Review
10.3 Target Analysis
10.4 Pursued Tumor Types
10.5 Biomarkers and Combination Therapies Review
10.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
10.7 Drug Innovators

11 ASCO 2017 by CAR/TCR Therapies
11.1 Pipeline Breakdown and Status
11.2 Compound Review
11.3 Target Analysis
11.4 Pursued Tumor Types
11.5 Biomarkers and Combination Therapies Review
11.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
11.7 Drug Innovators

12 ASCO 2017 by Immune Checkpoint Drugs
12.1 Compound Review
12.2 Target Analysis
12.3 Pursued Tumor Types
12.4 Biomarkers and Combination Therapies Review
12.5 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
12.6 Drug Innovators
13 ASCO 2017 by Epigenetic Therapies
13.1 Pipeline Breakdown and Status
13.2 Compound Review
13.3 Target Analysis
13.4 Pursued Tumor Types
13.5 Biomarkers and Combination Therapies Review
13.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
13.7 Drug Innovators

14 ASCO 2017 by DNA Damage Response Drugs
14.1 Pipeline Breakdown and Status
14.2 Compound Review
14.3 Target Analysis
14.4 Pursued Tumor Types
14.5 Biomarkers and Combination Therapies Review
14.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
14.7 Drug Innovators

15 ASCO 2017 by Protein Kinase Inhibitors
15.1 Pipeline Breakdown and Status
15.2 Compound Review
15.3 Target Analysis
15.4 Pursued Tumor Types
15.5 Biomarkers and Combination Therapies Review
15.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
15.7 Drug Innovators

16 ASCO 2017 by Antibody Drugs
16.1 Pipeline Breakdown and Status
16.2 Target Analysis
16.3 Pursued Tumor Types
16.4 Biomarkers and Combination Therapies Review
16.5 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
16.6 Drug Innovators

17 ASCO 2017 by Peptide Drugs
17.1 Pipeline Breakdown and Status
17.2 Target Analysis
17.3 Pursued Tumor Types
17.4 Biomarkers and Combination Therapies Review
17.5 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
17.6 Drug Innovators

18 ASCO 2017 by Nucleic Acid Therapies
18.1 Pipeline Breakdown and Status
18.2 Target Analysis
18.3 Pursued Tumor Types
18.4 Biomarkers and Combination Therapies Review
18.5 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
18.6 Drug Innovators

19 ASCO 2017 by Conjugated Drugs
19.1 Pipeline Breakdown and Status
19.2 Compound Review
19.3 Target Analysis
19.4 Pursued Tumor Types
19.5 Biomarkers and Combination Therapies Review
19.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
19.7 Drug Innovators

20 Disclaimer

21 Drug Index

22 Drug Innovator Index

 List of Figures
Figure 1: Pipeline Breakdown and Status of Cancer Drugs at ASCO 2017
Figure 2: Compound Review of Cancer Drugs at ASCO 2017
Figure 3: Target Analysis of Cancer Drugs at ASCO 2017
Figure 4: Pursued Tumor Types of Cancer Drugs at ASCO 2017
Figure 5: Biomarker Development and Combination Therapies among Cancer Drugs at ASCO 2017
Figure 6: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Cancer Drugs at ASCO 2017
Figure 7: Drug Innovators Behind Cancer Drugs at ASCO 2017
Figure 8: Pipeline Breakdown and Status of Startup Affiliated Drugs at ASCO 2017
Figure 9: Compound Review of Startup Affiliated Drugs at ASCO 2017
Figure 10: Target Analysis of Startup Affiliated Drugs at ASCO 2017
Figure 11: Pursued Tumor Types of Startup Affiliated Drugs at ASCO 2017
Figure 12: Biomarker Development and Combination Therapies among Startup Affiliated Drugs at ASCO 2017
Figure 13: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Startup Affiliated Drugs at ASCO 2017
Figure 14: Drug Innovators Behind Startup Affiliated Drugs at ASCO 2017
Figure 15: Pipeline Breakdown and Status of Fierce 15 Affiliated Drugs at ASCO 2017
Figure 16: Compound Review of Fierce 15 Affiliated Drugs at ASCO 2017
Figure 17: Target Analysis of Fierce 15 Affiliated Drugs at ASCO 2017
Figure 18: Pursued Tumor Types of Fierce 15 Affiliated Drugs at ASCO 2017
Figure 19: Biomarker Development and Combination Therapies among Fierce 15 Affiliated Drugs at ASCO 2017
Figure 20: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Fierce 15 Affiliated Drugs at ASCO 2017
Figure 21: Drug Innovators Behind Fierce 15 Affiliated Drugs at ASCO 2017
Figure 22: Pipeline Breakdown and Status of Orphan Drugs at ASCO 2017
Figure 23: Compound Review of Orphan Drugs at ASCO 2017
Figure 24: Target Analysis of Orphan Drugs at ASCO 2017
Figure 25: Pursued Tumor Types of Orphan Drugs at ASCO 2017
Figure 26: Biomarker Development and Combination Therapies among Orphan Drugs at ASCO 2017
Figure 27 Breakthrough Drugs and Sales Data Figures Among Orphan Drugs at ASCO 2017
Figure 28: Drug Innovators Behind Orphan Drugs at ASCO 2017
Figure 29: Pipeline Breakdown and Status of Breakthrough Therapy Drugs at ASCO 2017
Figure 30: Compound Review of Breakthrough Therapy Drugs at ASCO 2017
Figure 31: Target Analysis of Breakthrough Therapy Drugs at ASCO 2017
Figure 32: Pursued Tumor Types of Breakthrough Therapy Drugs at ASCO 2017
Figure 33: Biomarker Development and Combination Therapies among Breakthrough Therapy Drugs at ASCO 2017
Figure 34: Orphan Drugs and Sales Data Figures Among Breakthrough Therapy Drugs at ASCO 2017
Figure 35: Drug Innovators Behind Breakthrough Therapy Drugs at ASCO 2017
Figure 36: Pipeline Breakdown and Status of Cancer Vaccines at ASCO 2017
Figure 37: Compound Review of Cancer Vaccines at ASCO 2017
Figure 38: Target Analysis of Cancer Vaccines at ASCO 2017
Figure 39: Pursued Tumor Types of Cancer Vaccines at ASCO 2017
Figure 40: Biomarker Development and Combination Therapies among Cancer Vaccines at ASCO 2017
Figure 41: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Cancer Vaccines at ASCO 2017
Figure 42: Drug Innovators Behind Cancer Vaccines at ASCO 2017
Figure 43: Pipeline Breakdown and Status of CAR/TCR Therapies at ASCO 2017
Figure 44: Compound Review of CAR/TCR Therapies at ASCO 2017
Figure 45: Target Analysis of CAR/TCR Therapies at ASCO 2017
Figure 46: Pursued Tumor Types of CAR/TCR Therapies at ASCO 2017
Figure 47: Biomarker Development and Combination Therapies among CAR/TCR Therapies at ASCO 2017
Figure 48: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among CAR/TCR Therapies at ASCO 2017
Figure 49: Drug Innovators Behind CAR/TCR Therapies at ASCO 2017
Figure 50: Pipeline Breakdown and Status of Immune Checkpoint Drugs at ASCO 2017
Figure 51: Compound Review of Immune Checkpoint Drugs at ASCO 2017
Figure 52: Target Analysis of Immune Checkpoint Drugs at ASCO 2017
Figure 53: Pursued Tumor Types of Immune Checkpoint Drugs at ASCO 2017
Figure 54: Biomarker Development and Combination Therapies among Immune Checkpoint Drugs at ASCO 2017
Figure 55: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Immune Checkpoint Drugs at ASCO 2017
Figure 56: Drug Innovators Behind Immune Checkpoint Drugs at ASCO 2017
Figure 57: Pipeline Breakdown and Status of Epigenetic Therapies at ASCO 2017
Figure 58: Compound Review of Epigenetic Therapies at ASCO 2017
Figure 59: Target Analysis of Epigenetic Therapies at ASCO 2017
Figure 60: Pursued Tumor Types of Epigenetic Therapies at ASCO 2017
Figure 61: Biomarker Development and Combination Therapies among Epigenetic Therapies at ASCO 2017
Figure 62: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Epigenetic Therapies at ASCO 2017
Figure 63: Drug Innovators Behind Epigenetic Therapies at ASCO 2017
Figure 64: Pipeline Breakdown and Status of DNA Damage Response Drugs at ASCO 2017
Figure 65: Compound Review of DNA Damage Response Drugs at ASCO 2017
Figure 66: Target Analysis of DNA Damage Response Drugs at ASCO 2017
Figure 67: Pursued Tumor Types of DNA Damage Response Drugs at ASCO 2017
Figure 68: Biomarker Development and Combination Therapies among DNA Damage Response Drugs at ASCO 2017
Figure 69: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among DNA Damage Response Drugs at ASCO 2017
Figure 70: Drug Innovators Behind DNA Damage Response Drugs at ASCO 2017
Figure 71: Pipeline Breakdown and Status of Protein Kinase Inhibitors at ASCO 2017
Figure 72: Compound Review of Protein Kinase Inhibitors at ASCO 2017
Figure 73: Target Analysis of Protein Kinase Inhibitors at ASCO 2017
Figure 74: Pursued Tumor Types of Protein Kinase Inhibitors at ASCO 2017
Figure 75: Biomarker Development and Combination Therapies among Protein Kinase Inhibitors at ASCO 2017
Figure 76: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Protein Kinase Inhibitors at ASCO 2017
Figure 77: Drug Innovators Behind Protein Kinase Inhibitors at ASCO 2017
Figure 78: Pipeline Breakdown and Status of Cancer Antibodies at ASCO 2017
Figure 79: Target Analysis of Cancer Antibodies at ASCO 2017
Figure 80: Pursued Tumor Types of Cancer Antibodies at ASCO 2017
Figure 81: Biomarker Development and Combination Therapies among Cancer Antibodies at ASCO 2017
Figure 82: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Cancer Antibodies at ASCO 2017
Figure 83: Drug Innovators Behind Cancer Antibodies at ASCO 2017
Figure 84: Pipeline Breakdown and Status of Cancer Peptides at ASCO 2017
Figure 85: Target Analysis of Cancer Peptides at ASCO 2017
Figure 86: Pursued Tumor Types of Cancer Peptides at ASCO 2017
Figure 87: Biomarker Development and Combination Therapies among Cancer Peptides at ASCO 2017
Figure 88: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Cancer Peptides at ASCO 2017
Figure 89: Drug Innovators Behind Cancer Peptides at ASCO 2017
Figure 90: Pipeline Breakdown and Status of Nucleic Acid Therapies at ASCO 2017
Figure 91: Target Analysis of Nucleic Acid Therapies at ASCO 2017
Figure 92: Pursued Tumor Types of Nucleic Acid Therapies at ASCO 2017
Figure 93: Biomarker Development and Combination Therapies among Nucleic Acid Therapies at ASCO 2017
Figure 94: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Nucleic Acid Therapies at ASCO 2017
Figure 95: Drug Innovators Behind Nucleic Acid Therapies at ASCO 2017
Figure 96: Pipeline Breakdown and Status of Conjugated Drugs at ASCO 2017
Figure 97: Compound Review of Conjugated Drugs at ASCO 2017
Figure 98: Target Analysis of Conjugated Drugs at ASCO 2017
Figure 99: Pursued Tumor Types of Conjugated Drugs at ASCO 2017
Figure 100: Biomarker Development and Combination Therapies among Conjugated Drugs at ASCO 2017
Figure 101: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Conjugated Drugs at ASCO 2017
Figure 102: Drug Innovators Behind Conjugated Drugs at ASCO 2017

List of Tables
Table 1: Pipeline Table by Stage of Cancer Drugs at ASCO 2017
Table 2: Pipeline Table by Compound Type of Cancer Drugs at ASCO 2017
Table 3: Pipeline Table by Target of Cancer Drugs at ASCO 2017
Table 5: Pipeline Table by Tumor Type of Cancer Drugs at ASCO 2017
Table 6: Pipeline Table of Drugs with Biomarker Development and in Combination Therapies among Cancer Drugs at ASCO 2017
Table 7: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Cancer Drugs at ASCO 2017
Table 8: Pipeline Table by Drug Innovators Behind Cancer Drugs at ASCO 2017
Table 9: Pipeline Table by Highest Development Stage of Startup Affiliated Drugs at ASCO 2017
Table 10: Pipeline Table by Compound Type of Startup Affiliated Drugs at ASCO 2017
Table 11: Pipeline Table by Target of Startup Affiliated Drugs at ASCO 2017

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll